Form 4: Sangamo Therapeutics Director Robert Carey Receives Significant Equity Compensation

Sangamo Therapeutics, Inc. Director Robert Carey was granted 25,000 shares of common stock as Restricted Stock Units and 50,000 stock options on June 12, 2025, increasing his beneficial ownership.

Summary

• Robert Carey, a Director at Sangamo Therapeutics, Inc. (SGMO), acquired 25,000 shares of common stock through a Restricted Stock Unit (RSU) grant on June 12, 2025.
• These 25,000 RSU shares will fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on Mr. Carey's continuous service.
• Mr. Carey also acquired 50,000 stock options with an exercise price of $0.503 per share on June 12, 2025.
• The 50,000 stock options are immediately exercisable but subject to repurchase rights by the Issuer for unvested shares, with vesting occurring in 12 equal monthly installments following the grant date.
• Following these transactions, Mr. Carey beneficially owns 99,600 shares of common stock and 50,000 stock options.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive sign of alignment between management and shareholders, incentivizing long-term performance. It's a routine compensation event, not indicative of immediate operational changes, but reflects ongoing commitment.

Positives

• The grant of 25,000 Restricted Stock Units (RSUs) and 50,000 stock options to Director Robert Carey aligns his interests with shareholders, incentivizing long-term performance.
• The immediate exercisability of the stock options, despite vesting conditions, provides flexibility for the director.

Negatives

• The RSU grant and stock options were issued at a price of $0, indicating they are compensation grants rather than open market purchases, which might not signal direct confidence in current market price.
• The vesting schedules for both RSUs (until June 2026) and stock options (12 monthly installments) mean the full benefit is not immediately realized and is contingent on continuous service.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider equity transactions.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across the biotechnology and pharmaceutical industries to attract and retain executive talent and align their interests with long-term shareholder value. Such grants are standard components of executive compensation packages, particularly in companies like Sangamo Therapeutics that rely on long-term research and development cycles.

Comparison to Industry Standards

• Equity grants to directors, including a mix of restricted stock units and stock options, are standard compensation practices in the biotechnology sector.
• While specific grant sizes vary based on company size, performance, and individual roles, the structure observed here for Robert Carey at Sangamo Therapeutics is consistent with typical director compensation packages at comparable small to mid-cap biotech firms.
• For instance, companies like Editas Medicine (EDIT) or CRISPR Therapeutics (CRSP) also utilize similar equity-based incentives for their board members to foster long-term commitment and align interests with the company's strategic goals and scientific milestones.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. However, the issuance of new shares (upon vesting/exercise) could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The 25,000 RSU shares are expected to vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, subject to continuous service.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, SGMO, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Robert Carey